MedTrace Logo

Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer

NCT02550847 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-04-14

No results posted yet for this study

Summary

The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.

Conditions

Interventions

DEVICE

The imaging biomarkers determined by MR-PET

The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Ting-Fang Shih, MD · Department of Medical Imaging, National Taiwan University Hospital

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-04-30
Completion
2016-08-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02550847 on ClinicalTrials.gov